Mifepristone, a glucocorticoid receptor antagonist, produces clinical and metabolic benefits in patients with Cushing's syndrome

Cited by (481)

Items 101–200 of 481

1. Clinicopathological correlates of adrenal Cushing's syndrome
   Kai Duan, Karen Hernandez, Özgür Mete · 2014 · Journal of Clinical Pathology
2. Update on medical treatment for Cushing’s disease
   D. Cuevas-Ramos, D. Lim, M. Fleseriu · 2016 · Clinical Diabetes and Endocrinology
3. The Adrenal Cortex
   Paul M. Stewart, Nils Peter Krone · 2011 · Elsevier eBooks
4. Indole Glucocorticoid Receptor Antagonists Active in a Model of Dyslipidemia Act via a Unique Association with an Agonist Binding Site.
   John Gately Luz, Matthew W. Carson, Bradley Condon, David K. Clawson, Anna Pustilnik, Daniel T. Kohlman, Robert J. Barr, James S. Bean, M. Joelle Dill, Dana K. Sindelar et al. · 2015 · Journal of Medicinal Chemistry
5. New developments in the medical treatment of Cushing's syndrome
   Rob van der Pas, Wouter W. de Herder, Leo J. Hofland, Richard Abraham Feelders · 2012 · Endocrine Related Cancer
6. Italian Society for the Study of Diabetes (SID)/Italian Endocrinological Society (SIE) guidelines on the treatment of hyperglycemia in Cushing’s syndrome and acromegaly
   Baroni, M. G., Giorgino, F., Pezzino, V., Scaroni, C., Avogaro, A. · 2016 · Journal of Endocrinological Investigation
7. Effects of Chronic ACTH Excess on Human Adrenal Cortex
   XAVIER Y. BERTAGNA · 2017 · Frontiers in Endocrinology
8. Long‐term efficacy and safety of once‐monthly pasireotide in Cushing's disease: A Phase III extension study
   Maria Fleseriu, Stephan Petersenn, Beverly M. K. Biller, Pınar Kadıoğlu, Christophe E.M. De Block, Guy G. T'Sjoen, Marie‐Christine Vantyghem, Libuse Tauchmanovà, Judi Wojna, Michael Roughton et al. · 2019 · Clinical Endocrinology
9. Glucocorticoid-Induced Metabolic Disturbances Are Exacerbated in Obese Male Mice
   Innocence C. Harvey, Erin J. Stephenson, JeAnna R. Redd, Quynh T. Tran, Irit Hochberg, Nathan Qi, Dave Bridges · 2018 · Endocrinology
10. Mifepristone Treatment in Four Cases of Primary Bilateral Macronodular Adrenal Hyperplasia (BMAH)
    Pejman Cohan, Honey E. East, Sandi-Jo Galati, Jennifer U. Mercado, Precious J. Lim, Michele Lamerson, James J. Smith, Anne L. Peters, Kevin C.J. Yuen · 2019 · The Journal of Clinical Endocrinology & Metabolism
11. Clinical management of patients with Cushing syndrome treated with mifepristone: consensus recommendations
    David R. Brown, Honey E. East, Bradley Eilerman, Murray B. Gordon, Elizabeth E. King, Laura A. Knecht, Brandon Salke, Susan Leanne Samson, Kevin C.J. Yuen, Hanford Yau · 2020 · Clinical Diabetes and Endocrinology
12. Steroid hormones as modulators of anti-tumoural immunity
    Paul Schwarzlmueller, Alexandra S. Triebig, Guillaume Assié, Anne Jouinot, Sebastian Theurich, Tanja Maier, Felix Beuschlein, Sebastian Kobold, Matthias Kroiß · 2025 · Nature Reviews Endocrinology
13. Effects of Selective and Non-Selective Glucocorticoid Receptor II Antagonists on Rapid-Onset Diabetes in Young Rats
    Jacqueline Leah Beaudry, Emily C. Dunford, Trevor Teich, Dessi P. Zaharieva, Hazel Hunt, Joseph K. Belanoff, Michael Charles Riddell · 2014 · PLoS ONE
14. Update in the medical therapy of Cushing's disease
    Lynnette K. Nieman · 2013 · Current Opinion in Endocrinology Diabetes and Obesity
15. Management and Medical Therapy of Mild Hypercortisolism
    Vittoria Favero, Arianna Cremaschi, Alberto Falchetti, Agostino Gaudio, Luigi Gennari, Alfredo Scillitani, Fabio Vescini, Valentina Morelli, Carmen Aresta, Iacopo Chiodini · 2021 · International Journal of Molecular Sciences
16. Quality of Life and Other Outcomes in Children Treated for Cushing Syndrome
    Margaret F. Keil · 2013 · The Journal of Clinical Endocrinology & Metabolism
17. Drug-induced endocrine blood pressure elevation
    Katharina R. Beck, George R. Thompson, Alex Odermatt · 2019 · Pharmacological Research
18. Enhanced Antitumor Immunity via Endocrine Therapy Prevents Mammary Tumor Relapse and Increases Immune Checkpoint Blockade Sensitivity
    Gonzalo R. Sequeira, Ana Sahores, Tomás Dalotto‐Moreno, Ramiro M. Perrotta, Gabriela Pataccini, Silvia Inés Vanzulli, María L. Polo, Derek C. Radisky, Carol A. Sartorius, Virginia Novaro et al. · 2020 · Cancer Research
19. Drug Interaction Potential of Osilodrostat (LCI699) Based on Its Effect on the Pharmacokinetics of Probe Drugs of Cytochrome P450 Enzymes in Healthy Adults
    Sara Armani, Lillian S. L. Ting, Nicholas P. Sauter, Christelle Darstein, Anadya Prakash Tripathi, Lai Wang, Bing Yan Zhu, Helen Gu, Dung Yu Chun, Heidi J. Einolf et al. · 2017 · Clinical Drug Investigation
20. Cardiovascular risk and mortality in patients with active and treated hypercortisolism
    Li, Dingfeng, El Kawkgi, Omar M., Henriquez, Andres F., Bancos, Irina · 2020 · Gland Surgery
21. Mifepristone increases mRNA translation rate, triggers the unfolded protein response, increases autophagic flux, and kills ovarian cancer cells in combination with proteasome or lysosome inhibitors
    Lei Zhang, María Belén Hapon, Alicia Alejandra Goyeneche, Rekha Srinivasan, Carlos D Gamarra-Luques, Eduardo Alberto Callegari, Donis D. Drappeau, Erin J.M. Terpstra, Bo Pan, Jennifer R. Knapp et al. · 2016 · Molecular Oncology
22. Therapeutic options after surgical failure in Cushing's disease: A critical review
    German Rubinstein, Andrea Oßwald, Stephanie Zopp, Katrin Ritzel, Marily Theodoropoulou, Felix Beuschlein, Martín Reincke · 2019 · Best Practice & Research Clinical Endocrinology & Metabolism
23. The Interaction of Insulin and Pituitary Hormone Syndromes
    Marie Helene Schernthaner-Reiter, Peter S. Wolf, Greisa Vila, Anton Luger · 2021 · Frontiers in Endocrinology
24. Larval Zebrafish as a Model for Mechanistic Discovery in Mental Health
    Jazlynn Xiu Min Tan, Ryan Jun Wen Ang, Caroline Lei Wee · 2022 · Frontiers in Molecular Neuroscience
25. Adipose tissue in cortisol excess: What Cushing’s syndrome can teach us?
    Alessandro Bavaresco, Pierluigi Mazzeo, Martina Lazzara, Mattia Barbot · 2024 · Biochemical Pharmacology
26. Iatrogenic adrenal insufficiency in adults
    Julie Martin‐Grace, Maria Tomkins, Michael O’Reilly, Mark Sherlock · 2024 · Nature Reviews Endocrinology
27. Updates in the Medical Treatment of Pituitary Adenomas
    Monica Livia Gheorghiu, Francesca A. Negreanu, Maria Fleseriu · 2019 · Hormone and Metabolic Research
28. Cushing's syndrome
    Eleni Daniel, John D C Newell-Price · 2013 · Medicine
29. Metapristone suppresses non-small cell lung cancer proliferation and metastasis via modulating RAS/RAF/MEK/MAPK signaling pathway
    Guirong Zheng, Zhichun Shen, Hongning Chen, Jian Liu, Kai Jiang, Lulu Fan, Lee Jia, Jingwei Shao · 2017 · Biomedicine & Pharmacotherapy
30. Cushing's disease: current medical therapies and molecular insights guiding future therapies
    Darryl Lau, Caleb Rutledge, Manish Kumar Aghi · 2015 · Neurosurgical FOCUS
31. Quality of life in Cushing's syndrome.
    M. Bride, I. Crespo, S. Webb, E. Valassi · 2021 · Best practice & research. Clinical endocrinology & metabolism
32. Tumor Microenvironment in Adrenocortical Carcinoma: Barrier to Immunotherapy Success?
    Natalia Georgantzoglou, Stefania Kokkali, Gerasimos S. Tsourouflis, Stamatios E Theocharis · 2021 · Cancers
33. MRI–Negative Cushing's Disease: A Review on Therapeutic Management
    Mohammadmahdi Sabahi, Taha Shahbazi, Seyed Farzad Maroufi, Kevin Vidal, Pablo F. Recinos, Varun R. Kshettry, Florian Röser, Badih Adada, Hamid Borghei-Razavi · 2022 · World Neurosurgery
34. Pituitary-directed medical therapy with pasireotide for a corticotroph macroadenoma: pituitary volume reduction and literature review
    Ilan Shimon, Liat Rot, Edna Inbar · 2012 · Pituitary
35. The Treatment of Refractory Pituitary Adenomas
    Congxin Dai, Xiao-Hai Liu, Wenbin Ma, Renzhi Wang · 2019 · Frontiers in Endocrinology
36. Molecular basis of pharmacological therapy in Cushing’s disease
    Diego Ferone, Claudia Pivonello, Giovanni Vitale, Maria Chiara Zatelli, Annamaria Colao, Rosario Pivonello · 2013 · Endocrine
37. Update on the management of recurrent Cushing's disease
    Martin J. Rutkowski, Patrick Michael Flanigan, Manish Kumar Aghi · 2015 · Neurosurgical FOCUS
38. Sustained weight loss in patients treated with mifepristone for Cushing’s syndrome: a follow-up analysis of the SEISMIC study and long-term extension
    Henry G. Fein, Tom Brooks Vaughan, Harvey Kushner, David Cram, Dat Nguyen · 2015 · BMC Endocrine Disorders
39. An Open-label Phase I/IIa Clinical Trial of 11β-HSD1 Inhibitor for Cushing’s Syndrome and Autonomous Cortisol Secretion
    Satoko Oda, Kenji Ashida, Makiko Uchiyama, Shohei Sakamoto, Nao Hasuzawa, Ayako Nagayama, Lixiang Wang, Hiromi Nagata, Ryuichi Sakamoto, Junji Kishimoto et al. · 2021 · The Journal of Clinical Endocrinology & Metabolism
40. Mifepristone: is there a place in the treatment of Cushing’s disease?
    J. Carmichael, M. Fleseriu · 2013 · Endocrine
41. Pituitary Adenomas: What Are the Key Features? What Are the Current Treatments? Where Is the Future Taking Us?
    Domenico Solari, Rosario Pivonello, Chiara Caggiano, Elia Guadagno, Carmela Chiaramonte, Giovanni Miccoli, Luigi Maria Cavallo, Marialaura Del Basso De, Annamaria Colao, Paolo Cappabianca · 2019 · World Neurosurgery
42. Pasireotide
    Richard Abraham Feelders, Uma Yasothan, Peter N. Kirkpatrick · 2012 · Nature Reviews Drug Discovery
43. Nerves at Play: The Peripheral Nervous System in Extracranial Malignancies
    Paola Drapkin Vermeer, Anthony C. Restaino, Jeffrey L. Barr, Dan Yaniv, Moran Amit · 2025 · Cancer Discovery
44. Medical Management of Persistent and Recurrent Cushing Disease
    Maria Fleseriu · 2012 · Neurosurgery Clinics of North America
45. Endocrine Hypertension: A Practical Approach
    Joseph M Pappachan, Harit Buch · 2016 · Advances in experimental medicine and biology
46. Pituitary and SARS CoV-2: An unremitting conundrum
    Cristina Ana-Maria Capatina, Cătălina Poiană, Maria Fleseriu · 2023 · Best Practice & Research Clinical Endocrinology & Metabolism
47. Medical therapy for Cushing’s disease: adrenal steroidogenesis inhibitors and glucocorticoid receptor blockers
    Maria Fleseriu, Stephan Petersenn · 2015 · Pituitary
48. In Silico Drug Design Methods for Drug Repurposing
    Bashir Akhlaq Akhoon, Harshita Tiwari, Amit Nargotra · 2019 · Elsevier eBooks
49. Mifepristone Treatment for Mild Autonomous Cortisol Secretion Due to Adrenal Adenomas: A Pilot Study
    Regina Belokovskaya, Aarti Ravikumar, D. Arumugam, Sudeh Izadmehr, Gillian M. Goddard, Eliza Brevoort Geer, Alice C. Levine · 2019 · Endocrine Practice
50. E2F1-mediated human POMC expression in ectopic Cushing’s syndrome
    Takako Araki, Ning‐Ai Liu, Yukiko Tone, Daniel Cuevas Ramos, Roy Heltsley, Masahide Tone, Shlomo K. Melmed · 2016 · Endocrine Related Cancer
51. Medical Treatment of Cushing Disease
    Maria Fleseriu · 2014 · Endocrinology and Metabolism Clinics of North America
52. Cushing’s syndrome: an update on current pharmacotherapy and future directions
    Sara G Creemers, Leo J. Hofland, Steven W. J. Lamberts, Richard Abraham Feelders · 2015 · Expert Opinion on Pharmacotherapy
53. Recent Progress in the Medical Therapy of Pituitary Tumors
    Fabienne Langlois, Shirley McCartney, Maria Fleseriu · 2017 · Endocrinology and Metabolism
54. Mifepristone for Treatment of Metabolic Syndrome: Beyond Cushing’s Syndrome
    Francisco Díaz‐Castro, Matías Monsalves‐Álvarez, Leonel E. Rojo, Andrea del Campo, Rodrigo Troncoso · 2020 · Frontiers in Pharmacology
55. Glucocorticoid receptor blockers
    Mark E. Molitch · 2022 · Pituitary
56. Medical management of Cushing’s disease
    Nicholas A. Tritos, Beverly M. K. Biller · 2013 · Journal of Neuro-Oncology
57. Pituitary Masses and Tumors
    Shlomo K. Melmed, David L. Kleinberg · 2016 · Elsevier eBooks
58. An Individualized Approach to the Evaluation of Cushing Syndrome
    Susmeeta T. Sharma · 2017 · Endocrine Practice
59. Management of patients with persistent or recurrent Cushing’s disease after initial pituitary surgery
    Cristina Ana-Maria Capatina, José Miguel Hinojosa‐Amaya, Cătălina Poiană, Maria Fleseriu · 2020 · Expert Review of Endocrinology & Metabolism
60. Levoketoconazole in the Treatment of Patients With Cushing’s Syndrome and Diabetes Mellitus: Results From the SONICS Phase 3 Study
    R. Pivonello, A. Elenkova, M. Fleseriu, R. Feelders, P. Witek, Y. Greenman, E. Geer, P. Perotti, L. Saiegh, Fredric J. Cohen et al. · 2021 · Frontiers in Endocrinology
61. New avenues in the medical treatment of Cushing’s disease: corticotroph tumor targeted therapy
    Maria Fleseriu, Stephan Petersenn · 2013 · Journal of Neuro-Oncology
62. The importance of the hypothalamo-pituitary-adrenal axis as a therapeutic target in anorexia nervosa
    Bou Khalil, Rami, Souaiby, Lama, Farès, Nassim · 2017 · Physiology & Behavior
63. AACE/ACE Disease State Clinical Review: Medical Management of Cushing Disease
    Amir Hekmat Hamrahian, Kevin C.J. Yuen, Andrew R. Hoffman · 2014 · Endocrine Practice
64. Clinical Utility of Mifepristone: Apprising the Expanding Horizons
    Zalak Vinaybhai Karena, Harsh Shah, Hetvee Vaghela, Kalp Chauhan, Pranav K Desai, Asjad R Chitalwala · 2022 · Cureus
65. Association Between Mifepristone Dose, Efficacy, and Tolerability in Patients With Cushing Syndrome
    Kevin C.J. Yuen, Gavin Williams, Harvey Kushner, Dat Nguyen · 2015 · Endocrine Practice
66. Currently used and investigational drugs for Cushing´s disease
    Denis Ciato, Aizhar G. Mumbach, Marcelo Páez-Pereda, Günter Karl Stalla · 2016 · Expert Opinion on Investigational Drugs
67. Effect of 3 NR3C1 Mutations in the Pathogenesis of Pituitary ACTH Adenoma
    Hui Miao, Yang Liu, Lin Lü, Fengying Gong, Linjie Wang, Lian Duan, Yong Yao, Renzhi Wang, Shi Chen, Xinxin Mao et al. · 2021 · Endocrinology
68. Inadequately Controlled Type 2 Diabetes and Hypercortisolism: Improved Glycemia With Mifepristone Treatment
    Ralph Anthony DeFronzo, Vivian Andrew Fonseca, Vanita R. Aroda, Richard Joseph Auchus, Timothy Silleck Bailey, Irina Bancos, Robert S. Busch, John B. Buse, Elena A. Christofides, Bradley Eilerman et al. · 2025 · Diabetes Care
69. Glucocorticoid Receptor Antagonism Upregulates Somatostatin Receptor Subtype 2 Expression in ACTH-Producing Neuroendocrine Tumors: New Insight Based on the Selective Glucocorticoid Receptor Modulator Relacorilant
    Rosario Pivonello, Pamela N. Münster, Massimo Terzolo, Rosario Ferrigno, Chiara Simeoli, Soraya Puglisi, Utsav Bali, Andreas G. Moraitis · 2022 · Frontiers in Endocrinology
70. Improvement in Insulin Sensitivity During Mifepristone Treatment of Cushing Syndrome:Early and Late Effects
    Amisha Wallia, Kathleen Colleran, Jonathan Q. Purnell, Coleman Gross, Mark E. Molitch · 2013 · Diabetes Care
71. Antiprogestins in gynecological diseases
    Alicia Alejandra Goyeneche, Carlos Marcelo Telleria · 2014 · Reproduction
72. Role of skeletal muscle glucocorticoid receptor in systemic energy homeostasis
    Hirotoshi Tanaka, Noriaki Shimizu, Noritada Yoshikawa · 2017 · Experimental Cell Research
73. Advances in the Medical Treatment of Cushing Disease
    Nicholas A. Tritos, Beverly M. K. Biller · 2020 · Endocrinology and Metabolism Clinics of North America
74. Epidemiology and Management of Hypertension and Diabetes Mellitus in Patients with Mild Autonomous Cortisol Secretion: A Review
    Marta Araujo Castro, Martín Reincke, Cristina Lamas · 2023 · Biomedicines
75. Adrenal Mild Hypercortisolism
    Gillian M. Goddard, Aarti Ravikumar, Alice C. Levine · 2015 · Endocrinology and Metabolism Clinics of North America
76. Medical Therapy for Cushing’s Syndrome in the Twenty-first Century
    Tritos, Nicholas A., Biller, Beverly M.K. · 2018 · Endocrinology and Metabolism Clinics of North America
77. Levoketoconazole improves clinical signs and symptoms and patient-reported outcomes in patients with Cushing’s syndrome
    Eliza Brevoort Geer, Roberto Salvatori, Atanaska P. Elenkova, Maria Fleseriu, Rosario Pivonello, Przemysław Witek, Richard Abraham Feelders, Marie Bex, Stina Willemoes Borresen, Soraya Puglisi et al. · 2020 · Pituitary
78. Mifepristone Improves Adipose Tissue Insulin Sensitivity in Insulin Resistant Individuals
    Sriram Gubbi, Ranganath Muniyappa, Susmeeta T. Sharma, Shivraj Grewal, Raven McGlotten, Lynnette K. Nieman · 2021 · The Journal of Clinical Endocrinology & Metabolism
79. Osilodrostat improves blood pressure and glycemic control in patients with Cushing’s disease: a pooled analysis of LINC 3 and LINC 4 studies
    M. Fleseriu, R. Pivonello, J. Newell-Price, Mônica R. Gadelha, B. Biller, R. Auchus, R. Feelders, A. Shimatsu, P. Witek, M. Bex et al. · 2025 · Pituitary
80. De novo expression of functional connexins 43 and 45 hemichannels increases sarcolemmal permeability of skeletal myofibers during endotoxemia
    Luis A. Cea, Elisa Balboa, Aníbal A. Vargas, Carlos Puebla, María C. Brañes, Rosalba Escamilla, Tomás Regueira, Juan Carlos Sáez · 2019 · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease
81. Antiglucocorticoid therapy for older adults with anxiety and co-occurring cognitive dysfunction: results from a pilot study with mifepristone
    Eric J. Lenze, Tamara G. Hershey, John W. Newcomer, Jordan F. Karp, Daniel M. Blumberger, Jennifer T. Anger, Peter Doré, David J. Dixon · 2014 · International Journal of Geriatric Psychiatry
82. MANAGEMENT OF ENDOCRINE DISEASE: Can we cure Cushing’s disease? A personal view
    XAVIER Y. BERTAGNA · 2018 · European Journal of Endocrinology
83. Modulation of glucocorticoid receptor in human epileptic endothelial cells impacts drug biotransformation in an in vitro blood–brain barrier model
    Chaitali Ghosh, Mohammed Kamal Hossain, Saurabh Mishra, Sameena M. Khan, Jorge Alvaro Gonzalez-Martinez, Nicola Marchi, Damir Janigro, William E. Bingaman, Imad Najm · 2018 · Epilepsia
84. What is the role of medical therapy in adrenal-dependent Cushing’s syndrome?
    Braun, Leah T., Reincke, Martin · 2020 · Best Practice & Research Clinical Endocrinology & Metabolism
85. Ectopic ACTH-secreting pituitary adenomas within the sphenoid sinus
    Philip C Johnston, Laurence Kennedy, Robert John Weil, Amir Hekmat Hamrahian · 2014 · Endocrine
86. Current and Emerging Medical Therapies in Pituitary Tumors
    Nicolas Sahakian, Frédéric Castinetti, Thierry Christian Brue, Thomas Cuny · 2022 · Journal of Clinical Medicine
87. Genetically engineered human pituitary corticotroph tumor organoids exhibit divergent responses to glucocorticoid receptor modulators
    Saptarshi Mallick, Jayati L. Chakrabarti, Jennifer Mary Eschbacher, Andreas G. Moraitis, Andrew E. Greenstein, Jared M. Churko, Kelvin W. Pond, Antonia Livolsi, Curtis A. Thorne, Andrew S. Little et al. · 2023 · Translational research
88. The Adrenal Cortex
    Paul M. Stewart, John D C Newell-Price · 2016 · Elsevier eBooks
89. Mifepristone in the treatment of the ectopic adrenocorticotropic hormone syndrome
    Taweesak Wannachalee, Adina F. Turcu, Richard Joseph Auchus · 2018 · Clinical Endocrinology
90. Peripheral glucocorticoid receptor antagonism by relacorilant with modest HPA axis disinhibition
    Eva M. G. Viho, Jan Kroon, Richard Abraham Feelders, Renee Houtman, Elisabeth S R van den Dungen, Alberto M. Pereira, Hazel Hunt, Leo J. Hofland, Onno Cornelis Meijer · 2022 · Journal of Endocrinology
91. Cushing's disease
    Amandine Ferrière, Antoine Tabarin · 2021 · La Presse Médicale
92. The Evaluation and Treatment of Endocrine Forms of Hypertension
    Alejandro Velasco, Wanpen Vongpatanasin · 2014 · Current Cardiology Reports
93. Medical therapies in pituitary adenomas: Current rationale for the use and future perspectives
    Thomas Cuny, Anne Barlier, Richard Abraham Feelders, G. Weryha, Leo J. Hofland, Diego Ferone, Federico Gatto · 2014 · Annales d Endocrinologie
94. Adipocyte GR Inhibits Healthy Adipose Expansion Through Multiple Mechanisms in Cushing Syndrome
    Reiko Hayashi, Yosuke Okuno, Kosuke Mukai, Tetsuhiro Kitamura, Tomoaki Hayakawa, Toshiharu Onodera, Masahiko Murata, Atsunori Fukuhara, Ryoichi Imamura, Yasushi Miyagawa et al. · 2019 · Endocrinology
95. Adrenocortical Cancer Treatment
    Samuel E. Long, Barbra S. Miller · 2019 · Surgical Clinics of North America
96. Improvement but no normalization of quality of life and cognitive functioning after treatment for Cushing’s syndrome
    Broersen, Leonie H A, Andela, Cornelie D, Dekkers, Olaf M, Pereira, Alberto M, Biermasz, Nienke R · 2019 · The Journal of Clinical Endocrinology & Metabolism
97. Osilodrostat Treatment for Adrenal and Ectopic Cushing Syndrome: Integration of Clinical Studies With Case Presentations
    Maria Fleseriu, Richard Joseph Auchus, Irina Bancos, Beverly M. K. Biller · 2025 · Journal of the Endocrine Society
98. The management of Cushing's disease - from investigation to treatment.
    Agata Juszczak, Ashley Barry Grossman · 2013 · PubMed
99. Evaluation of FKBP5 as a cortisol activity biomarker in patients with ACTH-dependent Cushing syndrome
    Irina Bancos, Betül Hatipoğlu, Kevin C.J. Yuen, Lakshmi Chandramohan, Sandeep Chaudhari, Andreas G. Moraitis · 2021 · Journal of Clinical & Translational Endocrinology
100. Normalizing glucocorticoid levels attenuates metabolic and neuropathological symptoms in the R6/2 mouse model of huntington's disease
     Brett D. Dufour, Jodi L. McBride · 2018 · Neurobiology of Disease